Trial Profile
Value of usefulness of diffuse optical spectroscopic imaging for monitoring efficacy of aingle agent bevacizumab followed by Paclitaxel in breast cancer patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 16 May 2016 New trial record
- 03 May 2016 Results of poled analysis published in the British Journal of Cancer